Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MDGL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$205.25-0.8%$238.18$119.76▼$302.68$4.41B-0.33467,383 shs234,030 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals-0.81%-10.70%-16.11%+8.09%-29.74%Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDGLMadrigal Pharmaceuticals4.5863 of 5 stars4.41.00.04.61.74.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDGLMadrigal Pharmaceuticals2.73Moderate Buy$345.0968.13% UpsideCurrent Analyst RatingsLatest MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2024MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$270.00 ➝ $200.005/8/2024MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$389.00 ➝ $382.005/8/2024MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$425.00 ➝ $390.005/8/2024MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$397.00 ➝ $381.004/22/2024MDGLMadrigal PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$150.003/20/2024MDGLMadrigal PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$325.00 ➝ $405.003/15/2024MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$405.00 ➝ $425.003/15/2024MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$338.00 ➝ $377.003/15/2024MDGLMadrigal PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$320.00 ➝ $375.003/15/2024MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$351.00 ➝ $397.00(Data available from 5/11/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDGLMadrigal PharmaceuticalsN/AN/AN/AN/A$39.92 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDGLMadrigal Pharmaceuticals-$373.63M-$23.09N/AN/AN/AN/A-128.60%-78.52%8/13/2024 (Estimated)Latest MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024Q1 2024MDGLMadrigal Pharmaceuticals-$6.06-$7.38-$1.32-$7.38N/AN/A 2/28/2024Q4 2023MDGLMadrigal Pharmaceuticals-$5.26-$5.68-$0.42-$5.68N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDGLMadrigal Pharmaceuticals0.149.395.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipMDGLMadrigal Pharmaceuticals23.92%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMDGLMadrigal Pharmaceuticals37621.31 million16.21 millionOptionableMDGL HeadlinesSourceHeadlineLeerink Partnrs Brokers Reduce Earnings Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)americanbankingnews.com - May 11 at 2:12 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) PT Lowered to $200.00marketbeat.com - May 10 at 9:35 AMBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Start for Rezdifframarkets.businessinsider.com - May 10 at 9:24 AMLeerink Partnrs Comments on Madrigal Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:MDGL)marketbeat.com - May 10 at 7:06 AMJMP Securities Lowers Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $381.00americanbankingnews.com - May 10 at 6:52 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $382.00americanbankingnews.com - May 10 at 6:04 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $390.00americanbankingnews.com - May 10 at 6:04 AMMadrigal Pharmaceuticals: Strong Buy Rating Amidst Rapid Growth and Strategic Initiativesmarkets.businessinsider.com - May 8 at 6:56 PMSpotlight on Madrigal Pharmaceuticals: Analyzing the Surge in Options Activitybenzinga.com - May 8 at 6:56 PMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - May 8 at 6:56 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Cut to $382.00 by Analysts at Citigroupmarketbeat.com - May 8 at 4:00 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Posts Earnings Results, Misses Expectations By $1.32 EPSmarketbeat.com - May 8 at 11:00 AMBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Promising Launch of First Approved NASH Treatment and Strong Market Positioningmarkets.businessinsider.com - May 8 at 3:22 AMMadrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...finance.yahoo.com - May 8 at 3:22 AMBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid Financialsmarkets.businessinsider.com - May 7 at 10:16 PM‘Remarkable interest’: Madrigal touts early launch progress for first MASH drug Rezdiffra despite VA hurdlefiercepharma.com - May 7 at 5:12 PMMadrigal sees ‘tremendous interest’ in new NASH drug Rezdiffraseekingalpha.com - May 7 at 5:12 PMMDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024msn.com - May 7 at 5:12 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $235.57marketbeat.com - May 7 at 3:22 PMMadrigal: Q1 Earnings Snapshottimesunion.com - May 7 at 9:58 AMMadrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launchfinance.yahoo.com - May 7 at 9:58 AMMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updatesglobenewswire.com - May 7 at 7:00 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 8.2%americanbankingnews.com - May 5 at 6:50 AMCalifornia Public Employees Retirement System Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - May 5 at 5:12 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMadrigal PharmaceuticalsNASDAQ:MDGLMadrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
